Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Utilizing regorafenib in the treatment of patients with recurrent glioblastoma

Guiseppe Lombardi • 23 Oct 2023
ESMO 2023
Glioblastoma

Giuseppe Lombardi, MD, PhD, Veneto Institute of Oncology, Padua, Italy, discusses the use of regorafenib to treat patients with recurrent glioblastomas, elaborating on the necessity of finding biomarkers that predict patients who will likely have superior responses to the treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Guiseppe Lombardi

4:04
Latest updates in trials investigating treatments of neurological malignancies
Guiseppe Lombardi • 23 Oct 2023
3:30
Future directions in the treatment of glioblastoma
Guiseppe Lombardi • 23 Oct 2023
3:47
REGOMA-OS: a real-world study into the use of regorafenib for patients with recurrent glioblastoma
Guiseppe Lombardi • 23 Oct 2023

Related Videos

1:07
Genomic predictors of adverse events in glioblastoma
Patrick Wen • 12 Apr 2024
0:54
Identifying molecular biomarkers for treatment response to bortezomib in glioblastoma
Martha Chekenya • 7 Apr 2024
1:41
Sequential bortezomib and temozolomide in recurrent glioblastoma
Mohummad Rahman • 7 Apr 2024
3:13
Challenges in glioblastoma treatment: bortezomib trial for improved outcomes
Martha Chekenya • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals